8-K: Biote Corp. Strengthens Board with Appointment of Roystone Capital Founder Richard Barrera

Biote Corp. announced the appointment of Richard R. Barrera, founder and portfolio manager of Roystone Capital, to its Board of Directors, bringing extensive finance and investment expertise.

Summary

• On June 5, 2025, biote Corp.'s Board of Directors appointed Richard R. Barrera as a Class II independent director, effective immediately, to fill the vacancy left by Steven J. Heyer's resignation.
• Mr. Barrera's term as a director will expire at the Company's 2027 Annual Meeting of Stockholders.
• He will also serve as a member of the Nominating and Corporate Governance Committee.
• Mr. Barrera, age 53, is the Founder and Portfolio Manager of Roystone Capital, a New York-based hedge fund he established in 2012.
• His prior experience includes serving as a Partner and Co-Portfolio Manager at Redwood Capital (2009-2012) and Glenview Capital (2002-2009), and earlier roles at Gleacher & Co., JP Morgan, and Groupe Arnault's family office.
• He holds a Bachelor's degree in Finance and Accounting from The Wharton School of the University of Pennsylvania and an MBA from Harvard Business School.
• As a non-employee director, Mr. Barrera will receive an annual cash retainer of $50,000 and an initial equity award with a grant-date fair value of $337,500, consisting of stock options vesting over 36 months.
• He will also receive an annual equity award with a grant-date fair value of $216,000, prorated for his initial year, vesting on the earlier of the first anniversary or the day prior to the next annual meeting.
• All his equity awards will vest immediately upon a change in control of the Company.
• The Company and Mr. Barrera have entered into a standard indemnification agreement.

Sentiment

Score: 7

Explanation: The appointment of a highly experienced and independent director is a positive step for corporate governance and strategic oversight, aligning with shareholder interests. While not directly impacting financial results, it strengthens the company's leadership.

Positives

• The appointment of Richard R. Barrera, a seasoned investment professional with over 20 years of experience, is expected to bring valuable financial and operational expertise to the Board.
• Mr. Barrera's firm, Roystone Capital, is noted as one of Biote's top institutional shareholders, indicating strong alignment with long-term shareholder value creation.
• His determination as an independent director enhances corporate governance and oversight.
• His background, including roles at major investment firms and experience on the Finance and Audit Committees of Pacific Gas & Electric, suggests a strong understanding of financial strategy and risk management.

Risks

• The success of the Company's dietary supplements in achieving significant market acceptance among clinics, practitioners, and patients is not guaranteed.
• The Company and its customers rely on certain third parties for the manufacturing of bio-identical hormones, posing supply chain risks.
• The business is sensitive to regulatory, economic, environmental, and competitive conditions in various geographic regions.
• There is a risk that the Company may not be able to increase the use of the Biote Method by practitioners and clinics at the anticipated rate or at all.
• The Company faces significant competition within its industry.
• The impact of strategic acquisitions and the successful implementation of growth strategies are subject to uncertainties.
• The Company has a limited operating history, which can make future performance difficult to predict.
• The ability to protect intellectual property is crucial and subject to challenges.
• The industry is subject to heavy regulatory oversight, and changes in applicable laws or regulations could adversely affect the business.
• Changes to international tariffs, U.S. trade policy, or similar government actions, as well as geopolitical tensions, could impact operations.
• There is a risk of inability to profitably expand in existing markets and into new markets.
• The Company may be adversely impacted by other economic, business, and/or competitive factors, including natural disasters like hurricanes.
• Future exchange and interest rates could negatively affect financial performance.

Future Outlook

The Company aims to continue executing its growth plan and building long-term value for shareholders, leveraging the expertise of its Board members.

Management Comments

• Marc Beer, Executive Chairman of Biote, stated: "We are pleased to welcome Rich Barrera to Biote's Board of Directors. Rich has a distinguished background as an investment professional, founding Roystone Capital in 2012 and managing investment portfolios for more than 20 years."
• Mr. Beer also noted: "For the past few years, we've had the pleasure of working with Rich and his team at Roystone, which is one of Biote's top institutional shareholders. Rich is fully aligned with our strategy to build long-term value for shareholders and his expertise and insights will be especially valuable as we continue to execute our growth plan."

Industry Context

Biote operates in the preventive healthcare sector, focusing on personalized hormone optimization and therapeutic wellness solutions. The appointment of a director with extensive finance and investment management experience suggests a strategic focus on financial discipline, capital allocation, and potentially M&A activities to support the company's growth within this evolving healthcare niche.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of an experienced independent director, who is also associated with a top institutional shareholder, is likely to be viewed positively as it suggests enhanced oversight and alignment with long-term value creation.
• Management: The new director's expertise in finance and investment could provide valuable strategic guidance and challenge management constructively.

Next Steps

• Mr. Barrera's term as a Class II director will continue until the Company's 2027 Annual Meeting of Stockholders.
• He will receive annual equity awards on the date of each annual stockholder meeting, subject to his continued Board service.

Key Dates

Recommendation

Keywords

Biote Corp, BTMD, Board of Directors, Richard Barrera, Roystone Capital, Corporate Governance, SEC Filing, 8-K, Healthcare, Hormone Optimization, Investment Management, Independent Director